These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 16759051)

  • 1. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
    Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
    Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
    Zeller V; Truffot C; Agher R; Bossi P; Tubiana R; Caumes E; Jouan M; Bricaire F; Katlama C
    Clin Infect Dis; 2002 Mar; 34(5):662-7. PubMed ID: 11810599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
    French M; Keane N; McKinnon E; Phung S; Price P
    HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
    Phillips P; Bonner S; Gataric N; Bai T; Wilcox P; Hogg R; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2005 Nov; 41(10):1483-97. PubMed ID: 16231262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.
    de Boer MG; Kroon FP; Kauffmann RH; Vriesendorp R; Zwinderman K; van Dissel JT
    Neth J Med; 2003 Dec; 61(12):408-12. PubMed ID: 15025416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team.
    Aberg JA; Williams PL; Liu T; Lederman HM; Hafner R; Torriani FJ; Lennox JL; Dube MP; MacGregor RR; Currier JS;
    J Infect Dis; 2003 Apr; 187(7):1046-52. PubMed ID: 12660918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: data from a veteran cohort.
    Breaux K; Gadde S; Graviss EA; Rodriguez-Barradas MC
    AIDS Care; 2010 Jul; 22(7):886-94. PubMed ID: 20635253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy.
    Aberg JA; Chin-Hong PV; McCutchan A; Koletar SL; Currier JS
    Clin Infect Dis; 2002 Jul; 35(1):E8-E13. PubMed ID: 12060894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.
    Karakousis PC; Moore RD; Chaisson RE
    Lancet Infect Dis; 2004 Sep; 4(9):557-65. PubMed ID: 15336223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting.
    Manosuthi W; Chaovavanich A; Tansuphaswadikul S; Prasithsirikul W; Inthong Y; Chottanapund S; Sittibusaya C; Moolasart V; Termvises P; Sungkanuparph S
    J Infect; 2007 Nov; 55(5):464-9. PubMed ID: 17714788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.
    Lange CG; Valdez H; Medvik K; Asaad R; Lederman MM
    Clin Immunol; 2002 Feb; 102(2):154-61. PubMed ID: 11846457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mycobacterium avium complex disease in HIV seropositive patients: incidence and risk factors before and after the introduction of highly active antiretroviral treatments. Clinical Epidemiology Group of the Information and Care Center for Human Immunodeficiency].
    Mary-Krause M; Rabaud C; Jouan M; Obadia M; de la Blanchardière A; Raffi F; May T
    Pathol Biol (Paris); 2000 Jun; 48(5):495-504. PubMed ID: 10949848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion.
    Lederman HM; Williams PL; Wu JW; Evans TG; Cohn SE; McCutchan JA; Koletar SL; Hafner R; Connick E; Valentine FT; McElrath MJ; Roberts NJ; Currier JS;
    J Infect Dis; 2003 Dec; 188(12):1794-803. PubMed ID: 14673757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.
    Race EM; Adelson-Mitty J; Kriegel GR; Barlam TF; Reimann KA; Letvin NL; Japour AJ
    Lancet; 1998 Jan; 351(9098):252-5. PubMed ID: 9457095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.
    Phillips P; Chan K; Hogg R; Bessuille E; Black W; Talbot J; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2002 Feb; 34(3):371-8. PubMed ID: 11774085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.